Home » Stocks » MGTX

MeiraGTx Holdings PLC (MGTX)

Stock Price: $12.85 USD -0.32 (-2.43%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 583.20M
Revenue (ttm) 15.95M
Net Income (ttm) -65.93M
Shares Out 43.97M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $12.85
Previous Close $13.17
Change ($) -0.32
Change (%) -2.43%
Day's Open 13.25
Day's Range 12.50 - 13.45
Day's Volume 93,103
52-Week Range 11.35 - 18.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., p...

1 week ago - GlobeNewsWire

MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon

3 weeks ago - Zacks Investment Research

LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...

3 weeks ago - GlobeNewsWire

LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...

2 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pha...

Other stocks mentioned: KDMN
2 months ago - PRNewsWire

MGTX has early proof of concept data for ophthalmic rare disease indications using its gene therapies. It has inked two deals with Janssen, one of them quite lucrative.

3 months ago - Seeking Alpha

Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET

4 months ago - GlobeNewsWire

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...

5 months ago - GlobeNewsWire

LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...

5 months ago - GlobeNewsWire

The company announced the pricing of a public offering of common stock.

5 months ago - The Motley Fool

LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten p...

5 months ago - GlobeNewsWire

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwr...

5 months ago - GlobeNewsWire

Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal...

5 months ago - GlobeNewsWire

LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...

6 months ago - GlobeNewsWire

LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the thir...

6 months ago - GlobeNewsWire

12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented 12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented

6 months ago - GlobeNewsWire

LONDON and NEW YORK, Oct. 03, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month data from the ongoin...

7 months ago - GlobeNewsWire

LONDON and NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D...

7 months ago - GlobeNewsWire

- Nine-Month Follow-Up Data to be Presented - - Nine-Month Follow-Up Data to be Presented -

7 months ago - GlobeNewsWire

MeiraGTx Is A Buy With Multiple Near-Term Catalysts As The Stock Is Weighed Down By Negative Sentiment

8 months ago - Seeking Alpha

- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical trial - Expands manufacturing capabili...

9 months ago - GlobeNewsWire

LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. ...

9 months ago - GlobeNewsWire

MeiraGTx has been struggling lately, but the selling pressure may be coming to an end soon.

9 months ago - Zacks Investment Research

• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting 

9 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

MeiraGTx: An Exciting Gene Therapy Pick In March 2020

1 year ago - Seeking Alpha

LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines ...

1 year ago - GlobeNewsWire

Does MeiraGTx Holdings PLC (MGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Other stocks mentioned: CHRS, MRNA, QURE, XOMA
1 year ago - Zacks Investment Research

LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s di...

1 year ago - GlobeNewsWire

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: NTLA, PIRS, QURE, VRTX, GNOM
1 year ago - Zacks Investment Research

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: NTLA, PIRS, QURE, VRTX
1 year ago - Zacks Investment Research

See why Glu Mobile, MeiraGTx, and Enphase Energy should be on your shopping list.

Other stocks mentioned: ENPH, GLUU
1 year ago - The Motley Fool

LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present...

1 year ago - GlobeNewsWire

It was a great week for these three stocks, but can they continue climbing?

Other stocks mentioned: DOVA, KRYS
1 year ago - The Motley Fool

Can these high-flying biotech stocks keep the momentum going?

Other stocks mentioned: ADVM, IOVA
1 year ago - The Motley Fool

Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.

Other stocks mentioned: JNJ
1 year ago - Investors Business Daily

About MGTX

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentos... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Alexandria Forbes
Employees
219
Stock Exchange
NASDAQ
Ticker Symbol
MGTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for MGTX stock is "Strong Buy." The 12-month stock price forecast is 35.57, which is an increase of 176.81% from the latest price.

Price Target
$35.57
(176.81% upside)
Analyst Consensus: Strong Buy